Chronic wounds "must be addressed in DMP" (disease management programme):
This article was originally published in Clinica
Executive Summary
More attention must be paid to the treatment of open wounds in the German government's disease management programme (DMP) for diabetes mellitus type 2, says the medical device industry association, BVMed. The statement comes in response to the ministry of health's legislation on pre-requisites necessary to set up structured treatment programmes for the disease, published last month. BVMed estimates that the treatment of chronic wounds amounts to 25% of overall diabetes treatment costs. Some 4 million patients suffer from chronic wounds in Germany, and approximately 1 million of them are diabetics.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.